Heterotricyclic compounds for use as HCV inhibitors

1. A compound of formula II,

and pharmaceutically acceptable salts and N-oxides thereof wherein,

R 1 is, —OH, C 1 -C 6 -alkyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothienyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benz-1H-tetrazolyl, benz-2H-tetrazolyl, benz-3H-tetrazolyl, benz-4H-tetrazolyl, benz-5H-tetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H- 1,5,2-dithiazinyl, dihydrofuro [2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3 -oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thienyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3 ,4-triazolyl, benzodiazepinyl, xanthenyl, C 1 -C 6 -alkyl-OR 7 , C 1 -C 6 -alkyl-OH, aryl, halogen, cyano, —CO—H, —CO—OH, —CO—OR 7 , —CO—NH 2 , —CO—NHR 7 , —CO—NR 7 R 7 , —CO—NH—OH, —CO—NH—OR 7 , —CO—NR 7 —OH, —CO—N(R 7 )—OR 7 , —CO—R 7 ,C 1 -C 6 -alkyl-NH—OR 7 , C 1 -C 6 -alkyl-NH—OH, C 1 -C 6 -alkyl-NR 7 —OH, C 1 -C 6 -alkyl -NR 7 —OR 7 , C 1 -C 6 -alkyl-CO—NHOR 7 , C 1 -C 6 -alkyl-CO—NR 7 OR 7 , C 1 -C 6 -alkyl-CO—NHOH, C 1 -C 6 -alkyl-CO—NR 7 OH, —SO 2 R 7 , —SOR 7 , —SO 2 NH 2 , —SO 2 NHR 7 , —SO 2 NR 7 R 7 , —SO 2 -heteroaryl, —SO 2 -aryl, —SO 3 H, —SO 3 R 7 , —SO 2 Cl, —NHR 7 , C 1 -C 6 alkyl-NH(R 7 )-aryl, C 1 -C 6 -alkyl-NR 7 —OR 7 , —NH(R 7 )-aryl, —CO-heteroaryl, —NH—CO—O—R 7 -aryl, —NH—CO—NH—SO 2 -aryl, —NH—CO—OR 7 , —NH—CO—NH—(C 1 -C 6 -alkyl) or —NH—CO—(C 1 -C 6 -alkyl), wherein each of the alkyl, heterocyclyl, heteroaryl and aryl groups are optionally substituted with C 1 -C 6 -alkyl, nitro, hydroxy, C 1 -C 6 -alkoxy, —CO—O—(C 1 -C 6 -akyl), cyano, —O-halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 -alkyl) or halogen;

each of R 2 , R 4 , and R 5 is independently selected from hydrogen, nitro, —OH, C 1 -C 6 -alkyl, heterocyclyl, —O-halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 alkyl), C 1 -C 6 -alkyl-OR 7 , C 1 -C 6 -alkyl-OH, aryl, heteroaryl, heterocyclic, halogen, cyano, —OCF 3 , —CF 3 , azido, —O—(C 3 -C 6 -cycloalkyl), —S—(C 1 -C 6 -alkyl), C 1 -C 6 -alkoxy, —(C 1 -C 6 -alkoxy)-aryl, —CO—H, —CO—OH, —CO—OR 7 , —CO—NH 2 , —CO—NHR 7 , —CO—NR 7 R 7 , —CO—NH—OH, —CO—NH—OR 7 , —CO—NR 7 —OH, —CO—N(R 7 )—OR 7 , —CO—R 7 , C 1 -C 6 -alkyl-NH—OR 7 , C 1 -C 6 -alkyl-NH—OH, C 1 -C 6 -alkyl-NR 7 —OH, C 1 -C 6 -alkyl-NR 7 —OR 7 , C 1 -C 6 -alkyl-CO—NHOR 7 , C 1 -C 6 -alkyl-CO—NR 7 OR 7 , C 1 -C 6 -alkyl-CO—NHOH, C 1 -C 6 -alkyl-CO—NR 7 OH, —SO 2 R 7 , —SOR 7 , —SO 2 NH 2 , —SO 2 NHR 7 , —SO 2 NR 7 R 7 , —SO 2 -heteroaryl, —SO 2 -aryl, —SO 3 H, —SO 3 R 7 , —SO 2 Cl, —NH 2 , —NHR 7 , —NR 7 R 7 , C 1 -C 6 alkyl-NH(R 7 )—aryl, C 1 -C 6 -alkyl-NR 7 —OR 7 , —NH(R 7 )-aryl, —CO-heteroaryl, —N(R 7 )—CO-R 7 , —NH—SO 2 —R 7 , —N(R 7 )—CO—NR 7 R 7 , —NH—CO—O—R 7 -aryl, —NH—CO—NH—SO 2 -aryl, —NR 7 —CO—OR 7 , —NH—CO—OR 7 , —NH—CO—NH—(C 1 -C 6 -alkyl) or —NH—CO—(C 1 -C 6 -alkyl), wherein each of the alkyl, heterocyclyl, heteroaryl and aryl groups are optionally substituted with C 1 -C 6 -alkyl, nitro, hydroxy, C 1 -C 6 -alkoxy, —CO—O—(C 1 -C 6 akyl), cyano, —O-halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 -alkyl) or halogen; or

R 4 and R 5 together with the carbon atoms to which they are attached form an aryl, heterocyclyl or heteroaryl; or

R 1 is a group selected from

wherein X is ═NH or ═S, Y is ═N—, R 8 is hydrogen or hydroxy, R 9 is hydroxy, C 1 -C 6 -alkoxy or aryl optionally substituted with hydroxy or C 1 -C 6 -alkyl; and

and R 2 is H or a group selected from

wherein X is ═NH or ═S, Y is ═N—, R 8 is hydrogen or hydroxy, R 9 is hydroxy, C 1 -C 6 -alkoxy or aryl optionally substituted with hydroxy or C 1 -C 6 -alkyl; or

R 1 and R 2 together with the carbon atoms to which they are attached form a mono or bicyclic aryl or heteroaryl;

each of R 10 , R 11 , and R 12 is independently selected from hydrogen, —CN, —NO 2 , —OH, C 1 -C 6 -alkyl, aryl, C 1 -C 6 -alkyl-aryl, —O-halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 -alkyl), —O—(C 3 -C 6 -cycloalkyl), —S—(C 1 -C 6 -alkyl), heterocyclyl, C 1 -C 6 -alkoxy, —(C 1 -C 6 -alkoxy)-aryl, azido, halogen, —OCF 3 , —CF 3 , —CO—H, —CO—R 7 , —CO—OH, —CO—OR 7 , —CO—NH 2 , —CO—NHR 7 , —CO—NR 7 R 7 , —CO—N(R 7 )OR 7 , —CO—NR 7 OH, —CO—NHOR 7 , C 1 -C 6 -alkyl-CO—NHOR 7 , C 1 -C 6 -alkyl-CO—NR 7 OR 7 , C 1 -C 6 -alkyl-CO—NHOH, C 1 -C 6 -alkyl-CO—NR 7 OH, —CO—N(R 7 )OH, —CO—NHOH, —CO—H, —SO 2 —R 7 , —SO—R 7 , —SO—(C 1 -C 6 -alkyl), —SO 2 —(C 1 -C 6 -alkyl), —SO 2 NH 2 , —SO 2 NHR 7 , —SO 2 NR 7 R 7 , —CO—heteroaryl, C 1 -C 6 -alkyl-NH—OR 7 , C 1 -C 6 -alkyl-NH—OH, C 1 -C 6 -alkyl-NR 7 —OH, C 1 -C 6 -alkyl-NR 7 —OR 7 , NH 2 , —NHR 7 , —NR 7 R 7 , —N(R 7 )—CO—R 7 , —NHSO 2 R 7 , —N(R 7 )—CO—OR 7 or —N(R 7 )—CO—NR 7 R 7 , wherein each of the alkyl, alkoxy, aryl, heteroaryl and heterocyclyl are optionally substituted with one or more halogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, —OCF 3 , —CF 3 , —CN, —NH 2 , —NO 2 , —OH, mono- or di- C 1 -C 6 -alkylamino, or oxo;

R 7 is hydrogen, C 1 -C 6 -alkyl, —(C 1 -C 6 -alkyl)—OH, —(C 1 -C 6 -alkyl)—O—(C 1 -C 6 -alkyl), —(C 1 -C 6 -alkyl)—CN, C 2 -C 6 -alkene, heterocyclyl, aryl, heteroaryl or —(C 1 -C 6 -alkyl)-aryl, wherein each of the aryl, heterocyclyl and heteroaryl groups are optionally substituted with C 1 -C 6 -alkyl, nitro, hydroxy, C 1 -C 6 -alkoxy, —CO—O—(C 1 -C 6 -alkyl), cyano, —O- halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 alkyl) or halogen;

A 1 , A 2 , A 3 , and A 4 are each N;

B 1 is S, B 4 is a bond, and B 2 and B 3 are C, the R group attached to B 1 and B 4 , R 3 and R 6 , respectively, are absent and the B ring is a five membered ring; and

the dashed lines of rings A, B and C represent single or double bonds such that each annular N has three bonds, each annular O has two bonds, each annular S has two bonds and each annular C has four bonds.

2. A compound according to claim 1 of the formula

and pharmaceutically acceptable salts and N-oxides thereof wherein

R 1 is —OH, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-OR 7 , C 1 -C 6 -alkyl-OH, aryl, acridinyl, benzimidazolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benz-1H-tetrazolyl, benz-2H-tetrazolyl, benz-3H-tetrazolyl, benz-4H-tetrazolyl, benz-5H-tetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, cinnolinyl, furanyl, furazanyl, imidazolyl, 1H-indazolyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thienyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, halogen, —CO—H, —CO—OH, —CO—OR 7 , —CO—NH 2 , —CO—NHR 7 , —CO—NR 7 R 7 , —CO—NH—OH, —CO—NH—OR 7 , —CO—NR 7 —OH, —CO—N(R 7 )—OR 7 , —CO—R 7 , C 1 -C 6 -alkyl-NH—OR 7 , C 1 -C 6 -alkyl-NH—OH, C 1 -C 6 -alkyl-NR 7 —OH, C 1 -C 6 -alkyl-NR 7 —OR 7, C 1 -C 6 -alkyl-CO—NHOR 7 , C 1 -C 6 -alkyl -CO—NR 7 OR 7 , C 1 -C 6 -alkyl-CO—NHOH, C 1 -C 6 -alkyl—CO—NR 7 OH, —SO 2 R 7 , —SOR 7 , —SO 2 NH 2 , —SO 2 NHR 7 , —SO 2 NR 7 R 7 , —SO 2 heteroaryl, ——SO 2 -aryl, —SO 3 H, —SO 3 R 7 , —SO 2 Cl, —SO 2 NHR 7 , —SO 2 N(R 7 ), —NHR 7 , C 1 -C 6 alkyl-NH(R 7 )-aryl, C 1 -C 6 -alkyl-NR 7 —OR 7 , —NH(R 7 )-aryl, —CO—heteroaryl, —NH—CO—O—R 7 -aryl, —NH—CO—NH—SO 2 -aryl, —NH—CO—OR 7 , —NH—CO—NH—(C 1 -C 6 -alkyl) or —NH—CO—( C 1 -C 6 -alkyl), wherein each of the alkyl, heterocyclyl, heteroaryl and aryl groups are optionally substituted with C 1 -C 6 -alkyl, nitro, hydroxy, C 1 -C 6 -alkoxy, —CO—O—(C 1 -C 6 -akyl), cyano, —O-halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 -alkyl) halogen;

R 2 is hydrogen, —OH, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl-OR 7 , C 1 -C 6 -alkyl-OH, aryl, heteroaryl, halogen, —CO—H, —CO—OH, —CO—OR 7 , —CO—NH 2 , —CO—NHR 7 , —CO—NR 7 R 7 , —CO—NH—OH, —CO—NH—OR 7 , —CO—NR 7 —OH, —CO—N(R 7 )—OR 7 , —CO—R 7 , C 1 -C 6 -alkyl-NH—OR 7 , C 1 -C 6 -alkyl-NH—OH, C 1 -C 6 -alkyl-NR 7 —OH, C 1 -C 6 -alkyl-NR 7 —OR 7 , C 1 -C 6 -alkyl-CO—NHOR 7 , C 1 -C 6 -alkyl-CO—NR 7 OR 7 , C 1 -C 6 -alkyl-CO—NHOH, C 1 -C 6 -alkyl-CO—NR 7 OH, —SO 2 R 7 , —SOR 7 , —SO 2 NH 2 , —SO 2 NHR 7 , —SO 2 NR 7 R 7 , —SO 2 heteroaryl, —SO 2 -aryl, —SO 3 H, —SO 3 R 7 , —SO 2 Cl, —SO 2 NHR 7 , —SO 2 N(R 7 ), —NHR 7 , C 1 C 6 alkyl-NH(R 7 )-aryl, C 1 -C 6 -alkyl-NR 7 —OR 7 , —NH(R 7 )-aryl, —CO-heteroaryl, —NH—CO—O—R 7 -aryl, —NH—CO—NH—SO 2 -aryl, —NH—CO—OR 7 , —NH—CO—NH—(C 1 -C 6 -alkyl) or —NH—CO—(C 1 -C 6 -alkyl), wherein each of the alkyl, heterocyclyl, heteroaryl and aryl groups are optionally substituted with C 1 -C 6 -alkyl, nitro, hydroxy, C 1 -C 6 -alkoxy, —CO—O—(C 1 -C 6 -akyl), cyano, —O- halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 -alkyl) or halogen; or

wherein X is ═NH or S, Y is ═N—, R 8 is hydrogen or hydroxy, R 9 is hydroxy, C 1 -C 6 -alkoxy or aryl optionally substituted with hydroxy or C 1 -C 6 -alkyl; or

R 4 , and R 5 are independently hydrogen, nitro, C 1 -C 6 -alkyl, aryl, —O-halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 -alkyl), —O—(C 3 -C 6 -cycloalkyl), —S—(C 1 -C 6 -alkyl), —SO—(C 1 -C 6 -alkyl), —SO 2 —(C 1 -C 6 -alkyl), heterocyclyl, C 1 -C 6 -alkoxy, —(C 1 -C 6 -alkoxy)-aryl, azido, halogen, —OCF 3 , —CF 3 , —CO—H, —CO—OH, —CO—OR 7 , —CO—NH 2 , —CO—NHR 7 , —CO—NR 7 R 7 , —CO—N(R 7 )OR 7 , —CO—R 7 , —CO—NHOH, —CO—NHOR 7 , —CO—NR 7 OH, —CO—NR 7 OR 7 , —SO 2 —(C 1 -C 6 -alkyl), —SO 2 NH 2 , —SO 2 NHR 7 , —SO 2 NR 7 R 7 , —CO-heteroaryl, —NH 2 , —NHR 7 , —NR 7 R 7 , —OH, —N(R 7 )—CO-R 7 , —NHSO 2 R 7 , —N(R 7 )—CO—OR 7 , —N(R 7 )—CO—NR 7 R 7 ,

R 4 and R 5 together with the carbon atoms to which they are attached form a heteroaryl;

R 7 is hydrogen, C 1 -C 6 -alkyl, —(C 1 -C 6 -alkyl)—OH, —(C 1 -C 6 -alkyl)—O—(C 1 -C 6 alkyl), —(C 1 -C 6 -alkyl)—CN, C 2 -C 6 -alkene, heterocyclyl, aryl, heteroaryl or —(C 1 -C 6 -alkyl)-aryl, wherein each of the aryl, heterocyclyl and heteroaryl groups are optionally substituted with C 1 -C 6 -alkyl, nitro, hydroxy, C 1 -C 6 -alkoxy, —CO—O—(C 1 -C 6 -alkyl), cyano, —O— halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 -alkyl) or halogen;

R 10 , R 11 , and R 12 are independently hydrogen, —CN, —NO 2 , —OH, C 1 -C 6 -alkyl, aryl, C 1 -C 6 -alkyl-aryl, —O-halo(C 1 -C 6 -alkyl), halo(C 1 -C 6 -alkyl), —O—(C 3 -C 6 -cycloalkyl), —S—(C 1 -C 6 -alkyl), —SO—(C 1 -C 6 -alkyl), —SO 2 —(C 1 -C 6 -alkyl), heterocyclyl, C 1 -C 6 -alkoxy, —(C 1 -C 6 -alkoxy)-aryl, azido, halogen, —OCF 3 , —CF 3 , —CO—R 7 , —CO—OH, —CO—OR 7 , —CO—NH 2 , —CO—NHR 7 , —CO—NR 7 R 7 , —CO—N(R 7 )OR 7 , —CO—NHOR 7 , C 1 -C 6 -alkyl-CO—NHOR 7 , C 1 -C 6 -alkyl-CO—NR 7 OR 7 , C 1 -C 6 -alkyl-CO—NHOH, C 1 -C 6 -alkyl-CO—NR 7 OH, —CO—N(R 7 )OH, —CO—NHOH, —CO—H, —SO 2 —R 7 , —SO—R 7 , —SO 2 —(C 1 -C 6 -alkyl), —SO 2 NH 2 , —SO 2 NHR 7 , —SO 2 NR 7 R 7 , —CO- heteroaryl, C 1 -C 6 -alkyl-NH—OR 7 , C 1 -C 6 -alkyl-NH—OH, C 1 -C 6 -alkyl-NR 7 —OH, C 1 -C 6 -alkyl-NR 7 —OR 7 , NH 2 , —NHR 7 , —NR 7 R 7 , —N(R 7 )—CO—R 7 , —NHSO 2 R 7 , —N(R 7 )—CO—OR 7 or —N(R 7 )—CO—NR 7 R 7 , wherein each of the alkyl, alkoxy, aryl, heteroaryl and heterocyclyl are optionally substituted with one or more halogen, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, —OCF 3 , —CF 3 , —CN, —NH 2 , —NO 2 , —OH, mono- or di- C 1 -C 6 -alkylamino, or oxo.

3. The compound according to claim 2 wherein the dashed lines of ring B are independently single or double bonds such that the annular S has two bonds and each annular C has four bonds; R2,R4, R5 and R 10 to R 12 are hydrogen; R 1 is

wherein R 9 is hydroxy or C 1 -C 3 -alkoxy, —CO—H, —CO—OH, —CO—NH—OH, or —CO—NH—OR 7 , wherein R 7 is a heterocyclyl, wherein the heterocyclyl groups is optionally substituted with C 1 -C 6 -alkyl, hydroxy, C 1 -C 6 -alkoxy, cyano, or halogen.

4. The compound according to claim 3 , wherein the R 9 is methoxy.

5. The compound according to claim 3 wherein the heterocyclyl is pyranyl.

6. The compound according to claim 5 , wherein the heterocyclyl is pyran-2-yl.

7. The compound according to claim 3 that is selected from the group consisting of

tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxylic acid;

N-(tetrahydro-2H-pyran-2-yloxy)tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxamide;

N-hydroxytetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carboxamide;

tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carbaldehyde;

tetrazolo[1,5-a]thieno[2,3-e]pyridine-4-carbaldehyde O-methyloxime; and

and pharmaceutically acceptable salts and N-oxides thereof.

8. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carder.

9. A method of inhibiting HCV proliferation in vitro comprising contacting an HCV infected cell with a compound according to claim 1 .

10. A method of treating a mammal infected with an HCV infection, the method comprising administering to the mammal a therapeutically effective amount of a composition according to claim 8 .

11. The method according to claim 10 wherein the mammal is a human.